BTK inhibitor (Merck Research Laboratories/WuXi Pharma Tech Co.)

N/A

Report date: 2025/03/14 16:20:58
NME

Base Information

Drug NameBTK inhibitor (Merck Research Laboratories/WuXi Pharma Tech Co.)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesMerck Research Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesMerck Research LaboratoriesWuxi Apptec Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A